Radionetics Oncology Raises $52.5 Million Series A To Advance First-In-Class Radiopharmaceutical Pipeline And Announces The Appointment Of Industry Leader, Paul Grayson, As Ceo
Amount Raised
$52.5 Million
Round Type
Series A
Menlo ParkPharmaceutical ManufacturingInvestors
Description
Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences, 5AM Ventures, and new investor, DCVC Bio, with participation from Crinetics Pharmaceuticals, and GordonMD Global Investments, bringing the total raised to date to $82.5 million. Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.
Quick answer
Radionetics Oncology raised $52.5 Million in a Series A round, dated January 3, 2024. Investors: Radionetics, Gordon Md Global Investments, Crinetics Pharmaceuticals, DCVC Bio, 5 Am Ventures and Frazier Life Sciences. Radionetics Oncology is based in Menlo Park, California, United States.
- How much did Radionetics Oncology raise?
- Radionetics Oncology raised $52.5 Million in a Series A round on January 3, 2024.
- Who invested in Radionetics Oncology?
- Radionetics, Gordon Md Global Investments, Crinetics Pharmaceuticals, DCVC Bio, 5 Am Ventures and Frazier Life Sciences are named as investors in this round.
- What does Radionetics Oncology do?
- Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications.
- Where is Radionetics Oncology based and how big is it?
- Radionetics Oncology is based in Menlo Park, California, United States.
- Who are the decision-makers at Radionetics Oncology?
- Fundz holds 1 contact at Radionetics Oncology. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Pharmaceutical Manufacturing around the same time
Companies in the same sectors as Radionetics Oncology that raised within 45 days of this round, from Fundz verified event records.
- COUR Pharmaceuticals raised $105M (Funding Round) on February 11, 2024.
- DUDE CHEM raised $6.5M (Funding Round) on February 7, 2024.
- Orexa raised $940K (Seed) on February 2, 2024.
- COUR Pharmaceuticals raised $105M (Series A) on January 30, 2024.
- 3Daughters raised $2M (Seed) on January 22, 2024.
- Comanche Biopharma raised $75M (Series B) on January 18, 2024.
Who to call at Radionetics Oncology, and when
A new round usually means Radionetics Oncology is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Radionetics Oncology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Radionetics Oncology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Radionetics Oncology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Radionetics Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRadionetics Oncology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.